Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: Gilead Sciences vs. CymaBay Therapeutics

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. from 2014 to 2023. Over this period, Gilead Sciences consistently outspent CymaBay, with SG&A expenses peaking at approximately $6.09 billion in 2023, marking a 104% increase from 2014. In contrast, CymaBay's expenses grew by 535%, reaching around $51.95 million in 2023. This stark difference highlights Gilead's expansive operational scale compared to CymaBay's more modest growth trajectory. The data underscores the diverse financial strategies within the pharmaceutical sector, reflecting each company's unique market positioning and operational priorities. As the industry continues to innovate, these trends offer valuable insights into the financial health and strategic focus of these two companies.